Separovic L, Zhan Y, Kaweski SE, Sabaiduc S, Caraz. Interim estimates of vaccine effectiveness against influenza A(H1N1)pdm09 and A(H3N2) during a delayed influenza season, Canada, 2024/25. Euro Surveill. 2025 Jan;30(4)
The Canadian Sentinel Practitioner Surveillance Network (SPSN) reports interim 2024/25 vaccine effectiveness (VE) against acute respiratory illness due to laboratory-confirmed influenza during a delayed season of predominant A(H1N1)pdm09 and lower A(H3N2) co-circulation. Through mid-January, the risk of outpatient illness due to influenza A is reduced by about half among vaccinated vs unvaccinated individuals. Adjusted VE is 53% (95% CI: 36-65) against A(H1N1)pdm09, comprised of clades 5a.2a and 5a.2a.1, and 54% (95% CI: 29-70) against A(H3N2), virtually all clade 2a.3a.1.
See Also:
Latest articles in those days:
- MHC class II functions as a host-specific entry receptor for representative human and swine H3N2 influenza A viruses 1 minute(s) ago
- Longitudinal Surveillance of Influenza A Virus Exposure in Wild Boars (Sus scrofa) in Spain (2015-2023): Serologic and Virologic Evidence of Subtype Infections and H5N1 Spillover Risk 3 minute(s) ago
- [preprint]Emergence and antigenic characterisation of influenza A(H3N2) viruses with hemagglutinin substitutions N158K and K189R during the 2024/25 influenza season 19 hours ago
- Epitope specificity shapes the CD4+ T cell response to influenza virus infection in mice 19 hours ago
- Vaccination against H5 HP avian influenza virus leads to persistent immune response in wild king penguins 1 days ago
[Go Top] [Close Window]
